Navigation Links
Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
Date:3/7/2008

LAUSANNE, Switzerland, March 7 /PRNewswire/ -- Galderma Pharma, S.A. announces an agreement with ZARS Pharma, Inc. giving Galderma exclusive rights for all markets outside the USA and Canada for promotion and distribution of a novel topical anesthetic cream. This partnership follows an agreement signed last year between Galderma and ZARS Pharma for the promotion and distribution of Pliaglis(TM) in the USA and Canada.

"This agreement gives us a new opportunity to contribute to progress in patient care worldwide," said Humberto C. Antunes, CEO of Galderma. "As the market for corrective and aesthetic procedures continues to grow, Pliaglis(TM), with its unique vehicle and comfort of use for both patient and doctor is poised to fill an important unmet need. This agreement is part of our strategy to offer a comprehensive range of products that improve corrective and aesthetic procedural outcomes and complement our current family of therapeutic Rx and OTC products throughout the world."

Pliaglis(TM) (lidocaine and tetracaine) Cream 7%/7% is the first FDA-approved prescription-strength lidocaine and tetracaine combination topical anesthetic cream indicated to provide topical local analgesia for superficial dermatological procedures such as, among others, dermal filler injections, facial laser resurfacing and laser-assisted tattoo removal.

Formulated in a unique cream vehicle, Pliaglis(TM) is easily applied to the skin and forms a pliable self-occlusive mask which is easily peeled off the skin prior to a procedure. Pliaglis(TM) is a versatile new tool for use in many of the most common corrective and aesthetic procedures. With proven clinical efficacy, a unique phase-changing vehicle and an onset of action between 20-30 minutes, Pliaglis(TM) represents a technological innovation in patient's comfort.

"We are convinced that Pliaglis(TM) will be very well received by dermatologists and other physicians in Europe and Asia," said Francois Fournier, Vice-President EURMEAAS (Europe, Middle-East, Africa, Australia and Asia).

The corrective and aesthetic procedures market has more than doubled in the last five years with doctors using topical anesthetics for one in four of those procedures.

Galderma launched Pliaglis(TM) earlier this year in the USA and expects to file it with the regulatory authorities in the main worldwide markets later in 2008.

This license follows several recent transactions aimed at enriching Galderma's product offering to dermatology patients.

About Galderma:

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully integrated specialty pharmaceutical company dedicated exclusively to dermatology. The Company has a presence in 65 countries with over 1000 sales representatives and is committed to improving the health of skin with an extensive line of products that treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancers and medical solutions for skin senescence.

Galderma's new centre in Sophia Antipolis, France is the largest facility in the world dedicated to Research and Development in dermatology.

Galderma leading brands include Differin(R), Rozex(R)/Metro(R), Clobex(R), Tri-Luma(R), Loceryl(R) and Cetaphil(R). Recently launched products include Pliaglis(TM), a topical anaesthetic for dermatologic procedures in the United States, Epiduo(R), an innovative combination product for the treatment of acne in Europe and Argentina and Dysport(R), an injectable neuro-modulator for the correction of wrinkles in Brazil and Argentina. The Company's website is http://www.galderma.com.

About ZARS Pharma:

ZARS Pharma is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs using proprietary drug delivery technologies, primarily in the area of pain management and dermatology. ZARS Pharma has developed a rich portfolio of proprietary products and product candidates based on the CHADD technology and on cream technologies (Peel and DuraPeel(TM)) that transform, or phase-change, from an initial liquid phase to a solid phase during application. ZARS Pharma's product portfolio includes two products that have been approved for marketing (Pliaglis(TM) and Synera, the latter marketed as Rapydan in Europe). ZARS Pharma currently has one product in a late-stage clinical trial that commenced in June 2007 (ThermoProfen(TM)) and four additional products that have entered various stages of clinical development. For more information on ZARS Pharma, please visit http://www.zars.com.

Differin(R), Metrogel(R), Clobex(R), Tri-Luma(R), Cetaphil(R) and Epiduo(R) are trademarks of Galderma Pharma S.A.

Pliaglis(TM) is a trademark of ZARS Pharma, Inc. and Dysport(R) is a trademark of Ipsen Ltd.


'/>"/>
SOURCE Galderma Pharma, S.A.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
2. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
3. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
4. TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
5. GeoPharma, Inc. to Present at the EdgeWater Research Investor Conference
6. FDA Extends Review Timeline for Additional Indication for Antibiotic DORIBAX(TM)
7. Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets
8. Conseco Files to Formally Extend Due Date for Annual Report on Form 10-K to March 17 and Reschedules Earnings Release and Investor Call
9. FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
10. Actavis Extends Portfolio With Four New Products in the U.S.
11. CDC Panel Urges Extending Flu Vaccine Coverage for Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global ... is recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, ... move to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice ...
(Date:1/21/2017)... Pekin, IL (PRWEB) , ... January 21, 2017 , ... ... disorders. Even when individuals experience the freedom of recovery, they often feel shame for ... abuse and post-traumatic stress disorder (PTSD). In the workshop, “Rising Strong in Life After ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and ... essential oils, announced the company had a successful visit to the 2017 ECRM Diet, ... gives companies that work in the nutritional, sports and health industries a chance to ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing in the ... is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, alumnus of ... asked of her new book, Marjorie says, “‘The Angel’ was written as a fairytale, ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast to ... ) today announced it will release results for the fourth quarter ... ... host a conference call at 4:30 PM ET on Wednesday, February ... full year 2016 financial results and other corporate activities. To participate ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)...  Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage ... announced new additions to its senior leadership team: ... and Daniel Geffken as interim Chief Financial ... , Pharm.D. has been promoted to Chief Clinical Development ... Doug and Daniel to our management team, as both ...
Breaking Medicine Technology: